RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines

Invest New Drugs. 2023 Apr;41(2):220-225. doi: 10.1007/s10637-023-01344-9. Epub 2023 Mar 29.

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy has become a research hotspot in the field of hematological malignancies. However, CAR-T cell therapy can lead to immunotherapy-associated side effects including cytokine release syndrome and neurotoxicity. Gene depletion of GM-CSF in CAR-T cells was found preventive against adverse effects, but additional transfections were required to produce CAR-T cells. In this study, we interrupted GM-CSF expression in CAR-T cells by inserting the GM-CSF shRNA-expression cassette in the CAR vector. Reduction of GM-CSF in CAR-T cells could decrease the level of several proinflammatory cytokines without hampering the killing capacity. The manufacture of GM-CSF knockdown CAR-T cells does not require complicated transfections, which makes it more practical and feasible for clinical application.

Keywords: Chimeric antigen receptor T cells; Cytokine release syndrome; GM-CSF; RNA silencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cytokines / metabolism
  • Granulocyte-Macrophage Colony-Stimulating Factor* / genetics
  • Granulocyte-Macrophage Colony-Stimulating Factor* / metabolism
  • Humans
  • RNA Interference
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Antigen, T-Cell / metabolism
  • Receptors, Chimeric Antigen* / genetics
  • T-Lymphocytes

Substances

  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Cytokines
  • Receptors, Chimeric Antigen
  • Receptors, Antigen, T-Cell